CLINICAL MANIFESTATIONS OF TOXIC ADENOMA AND TOXIC MULTINODULAR GOITER
Overview and Pathophysiology
Definition
Hyperthyroidism caused by hyperfunctioning thyroid adenoma(s) independent of TSH (thyrotropin) regulation.
Second most common cause of hyperthyroidism after Graves disease.
Somatic Mutations
Often related to activating mutations in the TSH receptor gene → constitutive thyroid hormone production.
Toxic Multinodular Goiter: Multiple nodules with similar mutations in some nodules, others differ in function.
Toxic Adenoma: Typically a single, autonomously functioning thyroid nodule.
Clinical Features Distinct from Graves Disease
Demographics
Patients usually >40 years old.
Often have a long-standing multinodular goiter or single thyroid nodule.
Cardiovascular Dominance
Marked shortness of breath, tachycardia, frequently atrial fibrillation.
Heart failure can occur, but no prolonged circulation time (unlike Graves).
Lack of Eye and Skin Findings
No ophthalmopathy, pretibial myxedema, or thyroid acropachy (common in Graves).
Possible mild eyelid retraction or eyelid lag, but minimal if any.
Less Severe Hypermetabolic Symptoms
Less muscle weakness, less weight loss, and lower nervous excitability compared to Graves.
Many female patients are postmenopausal → fewer menstrual cycle changes.
Hormone Levels
Moderate elevations in serum free T4 and total T3 (not as high as Graves).
Slight decrease in total and HDL cholesterol.
Radioactive Iodine Uptake and Imaging
Toxic Adenoma (Solitary Nodule)
High uptake localized in the hyperfunctioning nodule.
No uptake in the rest of the gland (“suppressed” normal thyroid).
Toxic Multinodular Goiter
One or more areas of focal increased uptake (hot nodules).
Remaining gland may show multiple “cold” (nonfunctioning) or normal areas.
Management
Symptomatic Control
β-Adrenergic blockers (e.g., propranolol) to manage palpitations, tremor, tachycardia.
Definitive Treatment
Thionamides (e.g., methimazole, propylthiouracil) → typically used short-term in elderly or cardiac-compromised patients to achieve euthyroidism before definitive therapy.
Unlike Graves disease, hyperthyroidism recurs if thionamides are withdrawn without further intervention.
Radioiodine Ablation → destroys hyperfunctioning nodule(s) over 2–4 months.
Most patients become euthyroid because normal thyroid tissue is suppressed and takes up little radioiodine.
Large toxic multinodular goiters may respond less to radioiodine → surgery is often preferred.
Surgery
Especially if goiter is very large, causing compressive symptoms, or if there is suspicion of malignancy.
Also for those who prefer surgical resolution or are not good candidates for radioiodine.
PATHOPHYSIOLOGY OF TOXIC ADENOMA AND TOXIC MULTINODULAR GOITER
Typical Patient Profile
Often an older adult (commonly middle-aged woman).
History of nontoxic (euthyroid) nodular goiter that later becomes hyperfunctional.
Cardiac Manifestations
High-output heart failure: Short circulation time with high venous pressure.
Palpitations, atrial fibrillation, dyspnea.
Fewer extrathyroidal findings compared to Graves disease (no ophthalmopathy, dermopathy, or muscle weakness typical of Graves).
Pathologic Findings
Single Toxic Adenoma
One enlarged hyperfunctioning nodule (often red in color).
Remaining gland is suppressed, smaller or nonfunctional.
Very rare to hear a bruit or feel a thrill.
Histology: Uniform hyperplasia of follicular cells with minimal papillary infolding, no lymphocytic infiltration.
Multinodular Goiter
Multiple nodules: Some hyperfunctioning (hot), others hypofunctioning (cold).
Possibly malignant or premalignant foci in one nodule.
